Long-term effects of finasteride on prostate specific antigen levels: Results from the prostate cancer prevention trial

Ruth Etzioni, Nadia Howlader, Pamela A. Shaw, Donna P. Ankerst, David F. Penson, Phyllis J. Goodman, Ian M. Thompson

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Purpose: Studies have shown that finasteride decreases prostate specific antigen (PSA) by approximately 50% during the first 12 months of use. We estimated the long-term effects of finasteride on PSA in men with and without a prostate cancer diagnosis at the end of the study. Materials and Methods: We analyzed serial PSA in participants in the Prostate Cancer Prevention Trial who had an end of study biopsy (928 with cancer and 8,620 with negative biopsy) or an interim diagnosis of prostate cancer (671). Linear mixed effects regression models were fit to longitudinal PSA values beginning 1 year after randomization. Results: In subjects with no cancer in the end of study biopsy PSA in the finasteride arm showed a median annual decrease of 5% after year 1, while PSA in the control arm showed an annual increase of 3% (p <0.001). In end of study cases PSA increased annually by 6% (placebo) and 7% (finasteride). In those with interim diagnoses PSA increased by 11% (placebo) and 15% (finasteride) each year prior to diagnosis. Cases with high grade disease (Gleason 7 and above) had greater PSA increases than cases with low grade disease (p <0.001). Conclusions: In men who have been receiving finasteride for more than 1 year time varying adjustment factors may be needed to determine whether PSA is in the normal range. In the Prostate Cancer Prevention Trial cohort the adjustment factor required to preserve median PSA increased from 2 at 24 months to 2.5 at 7 years after the initiation of finasteride.

Original languageEnglish (US)
Pages (from-to)877-881
Number of pages5
JournalJournal of Urology
Volume174
Issue number3
DOIs
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Finasteride
Prostate-Specific Antigen
Prostatic Neoplasms
Biopsy
Placebos
Random Allocation
Neoplasms
Reference Values

Keywords

  • Finasteride
  • Mass screening
  • Prostate
  • Prostate-specific antigen
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Etzioni, R., Howlader, N., Shaw, P. A., Ankerst, D. P., Penson, D. F., Goodman, P. J., & Thompson, I. M. (2005). Long-term effects of finasteride on prostate specific antigen levels: Results from the prostate cancer prevention trial. Journal of Urology, 174(3), 877-881. https://doi.org/10.1097/01.ju.0000169255.64518.fb

Long-term effects of finasteride on prostate specific antigen levels : Results from the prostate cancer prevention trial. / Etzioni, Ruth; Howlader, Nadia; Shaw, Pamela A.; Ankerst, Donna P.; Penson, David F.; Goodman, Phyllis J.; Thompson, Ian M.

In: Journal of Urology, Vol. 174, No. 3, 01.01.2005, p. 877-881.

Research output: Contribution to journalArticle

Etzioni, R, Howlader, N, Shaw, PA, Ankerst, DP, Penson, DF, Goodman, PJ & Thompson, IM 2005, 'Long-term effects of finasteride on prostate specific antigen levels: Results from the prostate cancer prevention trial', Journal of Urology, vol. 174, no. 3, pp. 877-881. https://doi.org/10.1097/01.ju.0000169255.64518.fb
Etzioni, Ruth ; Howlader, Nadia ; Shaw, Pamela A. ; Ankerst, Donna P. ; Penson, David F. ; Goodman, Phyllis J. ; Thompson, Ian M. / Long-term effects of finasteride on prostate specific antigen levels : Results from the prostate cancer prevention trial. In: Journal of Urology. 2005 ; Vol. 174, No. 3. pp. 877-881.
@article{037c2e7ef3a5447fa16afa695b3e86dd,
title = "Long-term effects of finasteride on prostate specific antigen levels: Results from the prostate cancer prevention trial",
abstract = "Purpose: Studies have shown that finasteride decreases prostate specific antigen (PSA) by approximately 50{\%} during the first 12 months of use. We estimated the long-term effects of finasteride on PSA in men with and without a prostate cancer diagnosis at the end of the study. Materials and Methods: We analyzed serial PSA in participants in the Prostate Cancer Prevention Trial who had an end of study biopsy (928 with cancer and 8,620 with negative biopsy) or an interim diagnosis of prostate cancer (671). Linear mixed effects regression models were fit to longitudinal PSA values beginning 1 year after randomization. Results: In subjects with no cancer in the end of study biopsy PSA in the finasteride arm showed a median annual decrease of 5{\%} after year 1, while PSA in the control arm showed an annual increase of 3{\%} (p <0.001). In end of study cases PSA increased annually by 6{\%} (placebo) and 7{\%} (finasteride). In those with interim diagnoses PSA increased by 11{\%} (placebo) and 15{\%} (finasteride) each year prior to diagnosis. Cases with high grade disease (Gleason 7 and above) had greater PSA increases than cases with low grade disease (p <0.001). Conclusions: In men who have been receiving finasteride for more than 1 year time varying adjustment factors may be needed to determine whether PSA is in the normal range. In the Prostate Cancer Prevention Trial cohort the adjustment factor required to preserve median PSA increased from 2 at 24 months to 2.5 at 7 years after the initiation of finasteride.",
keywords = "Finasteride, Mass screening, Prostate, Prostate-specific antigen, Prostatic neoplasms",
author = "Ruth Etzioni and Nadia Howlader and Shaw, {Pamela A.} and Ankerst, {Donna P.} and Penson, {David F.} and Goodman, {Phyllis J.} and Thompson, {Ian M.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1097/01.ju.0000169255.64518.fb",
language = "English (US)",
volume = "174",
pages = "877--881",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Long-term effects of finasteride on prostate specific antigen levels

T2 - Results from the prostate cancer prevention trial

AU - Etzioni, Ruth

AU - Howlader, Nadia

AU - Shaw, Pamela A.

AU - Ankerst, Donna P.

AU - Penson, David F.

AU - Goodman, Phyllis J.

AU - Thompson, Ian M.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Purpose: Studies have shown that finasteride decreases prostate specific antigen (PSA) by approximately 50% during the first 12 months of use. We estimated the long-term effects of finasteride on PSA in men with and without a prostate cancer diagnosis at the end of the study. Materials and Methods: We analyzed serial PSA in participants in the Prostate Cancer Prevention Trial who had an end of study biopsy (928 with cancer and 8,620 with negative biopsy) or an interim diagnosis of prostate cancer (671). Linear mixed effects regression models were fit to longitudinal PSA values beginning 1 year after randomization. Results: In subjects with no cancer in the end of study biopsy PSA in the finasteride arm showed a median annual decrease of 5% after year 1, while PSA in the control arm showed an annual increase of 3% (p <0.001). In end of study cases PSA increased annually by 6% (placebo) and 7% (finasteride). In those with interim diagnoses PSA increased by 11% (placebo) and 15% (finasteride) each year prior to diagnosis. Cases with high grade disease (Gleason 7 and above) had greater PSA increases than cases with low grade disease (p <0.001). Conclusions: In men who have been receiving finasteride for more than 1 year time varying adjustment factors may be needed to determine whether PSA is in the normal range. In the Prostate Cancer Prevention Trial cohort the adjustment factor required to preserve median PSA increased from 2 at 24 months to 2.5 at 7 years after the initiation of finasteride.

AB - Purpose: Studies have shown that finasteride decreases prostate specific antigen (PSA) by approximately 50% during the first 12 months of use. We estimated the long-term effects of finasteride on PSA in men with and without a prostate cancer diagnosis at the end of the study. Materials and Methods: We analyzed serial PSA in participants in the Prostate Cancer Prevention Trial who had an end of study biopsy (928 with cancer and 8,620 with negative biopsy) or an interim diagnosis of prostate cancer (671). Linear mixed effects regression models were fit to longitudinal PSA values beginning 1 year after randomization. Results: In subjects with no cancer in the end of study biopsy PSA in the finasteride arm showed a median annual decrease of 5% after year 1, while PSA in the control arm showed an annual increase of 3% (p <0.001). In end of study cases PSA increased annually by 6% (placebo) and 7% (finasteride). In those with interim diagnoses PSA increased by 11% (placebo) and 15% (finasteride) each year prior to diagnosis. Cases with high grade disease (Gleason 7 and above) had greater PSA increases than cases with low grade disease (p <0.001). Conclusions: In men who have been receiving finasteride for more than 1 year time varying adjustment factors may be needed to determine whether PSA is in the normal range. In the Prostate Cancer Prevention Trial cohort the adjustment factor required to preserve median PSA increased from 2 at 24 months to 2.5 at 7 years after the initiation of finasteride.

KW - Finasteride

KW - Mass screening

KW - Prostate

KW - Prostate-specific antigen

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=23744482617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744482617&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000169255.64518.fb

DO - 10.1097/01.ju.0000169255.64518.fb

M3 - Article

C2 - 16093979

AN - SCOPUS:23744482617

VL - 174

SP - 877

EP - 881

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -